Can I Take Resveratrol With Amlodipine?

How Amlodipine Is Metabolized and Why It Matters

Amlodipine is a dihydropyridine calcium channel blocker approved by the FDA for hypertension and chronic stable angina. The liver clears it almost entirely through cytochrome P450 3A4 (CYP3A4), producing inactive pyridine metabolites that are excreted in urine [1]. Because CYP3A4 handles roughly 50% of all marketed drugs, any substance that slows this enzyme raises amlodipine plasma concentrations above the intended therapeutic range [2].

CYP3A4 and plasma concentration

Amlodipine has a long half-life of 30 to 50 hours, so plasma levels build gradually over 7 to 8 days of dosing before reaching steady state [1]. That slow accumulation means CYP3A4 inhibition does not produce a sudden spike in blood levels. Instead, it nudges levels upward over days to weeks, which is why patients sometimes feel fine initially and only develop symptomatic hypotension two or three weeks after adding a new supplement.

What happens when CYP3A4 is slowed

When CYP3A4 activity decreases, the area under the concentration-time curve (AUC) for amlodipine rises. A well-studied parallel: co-administration of the moderate CYP3A4 inhibitor diltiazem increases amlodipine AUC by approximately 57% [3]. That figure gives a useful clinical benchmark. Resveratrol is not as potent an inhibitor as diltiazem, but human pharmacokinetic data confirm it does inhibit CYP3A4 at supplemental doses.

How Resveratrol Inhibits CYP3A4

Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenol found in red grape skins, red wine, and Japanese knotweed. It is sold as a supplement at doses ranging from 100 mg to 1,500 mg per capsule, far above the few milligrams present in a glass of wine.

In vitro evidence

Multiple in vitro studies have identified resveratrol as a competitive inhibitor of CYP3A4 [4]. Lab IC50 values alone do not predict clinical magnitude, but they confirm the mechanism is real and not merely theoretical.

Human pharmacokinetic data

A crossover pharmacokinetic study published in the British Journal of Clinical Pharmacology tested resveratrol 1,000 mg/day for four days in healthy volunteers and measured a statistically significant reduction in CYP3A4-mediated metabolism of a probe substrate [5]. The inhibition was described as mild-to-moderate, not equivalent to a strong inhibitor like ketoconazole. Still, with a long-half-life drug like amlodipine, even mild CYP3A4 inhibition adds up over time because each dose clears more slowly than the last.

Dose dependency

Resveratrol's CYP3A4 inhibition appears dose-dependent. At 100 to 250 mg/day, clinically meaningful inhibition is less documented. At 500 mg/day and above, the pharmacokinetic signal becomes detectable in human data [5]. Patients who buy "trans-resveratrol 1,000 mg" capsules and take two per day are operating in a zone where the interaction is biologically plausible and clinically relevant.

The Pharmacodynamic Layer: Additive Blood-Pressure Lowering

The interaction is not purely pharmacokinetic. Resveratrol itself lowers blood pressure through independent mechanisms.

Resveratrol's antihypertensive mechanisms

A 2015 meta-analysis of 17 randomized controlled trials (N=681 participants) published in the Journal of Hypertension found that resveratrol supplementation produced a statistically significant reduction in systolic blood pressure of 2.0 mmHg (95% CI: 3.5 to 0.5 mmHg) [6]. The authors attributed this to resveratrol's ability to increase nitric oxide bioavailability and reduce arterial stiffness. A 2021 systematic review in Nutrients (N=9 trials, 582 participants) confirmed that higher doses (above 300 mg/day) produced the largest reductions, reaching up to 4 mmHg systolic in hypertensive subjects [7].

Why 2 to 4 mmHg matters on top of amlodipine

Amlodipine 10 mg/day typically lowers systolic blood pressure by 10 to 14 mmHg in hypertensive adults [1]. A patient already well-controlled on amlodipine may have a systolic reading of 120 mmHg. Adding resveratrol-driven reductions of 2 to 4 mmHg, on top of a possible pharmacokinetically driven increase in amlodipine exposure, could push that same patient into a systolic range below 110 mmHg. That produces symptoms: lightheadedness on standing, fatigue, and compensatory tachycardia.

Orthostatic hypotension risk

Amlodipine already carries a package-insert warning for edema and hypotension, particularly at higher doses and in older adults [1]. Adding a supplement with additive vasodilatory properties to a drug with a 30 to 50 hour half-life leaves little room for rapid correction if blood pressure drops too low.

Resveratrol's Estrogenic Activity: A Secondary Concern

Resveratrol binds estrogen receptor alpha (ERα) with measurable affinity and acts as a phytoestrogen [8]. This is relevant to two groups of amlodipine patients.

Patients on concurrent hormone therapy

Women taking estrogen-containing HRT or oral contraceptives alongside amlodipine should know that resveratrol may compound estrogenic activity. Estrogens also affect CYP3A4 expression, adding another variable to drug metabolism [9].

Hormone-sensitive conditions

Any patient with a history of hormone-sensitive breast cancer, endometriosis, or uterine fibroids should discuss resveratrol's estrogenic activity with their oncologist or gynecologist before starting it, regardless of their cardiovascular medications. The FDA does not regulate supplements for these indications, and labeling rarely discloses the estrogenic receptor binding data.

Clinical Risk Stratification: Who Is at Highest Risk?

Not every patient on amlodipine faces the same level of concern. Risk scales with several identifiable factors.

Higher-risk profile

Patients at higher risk from this combination include: those taking amlodipine 10 mg/day (the maximum approved dose), adults over 65 (CYP3A4 activity naturally declines with age [2]), anyone with a baseline systolic blood pressure at or below 130 mmHg on current therapy, patients taking other CYP3A4 inhibitors (azithromycin, fluconazole, grapefruit juice), and anyone with concurrent heart failure or severe aortic stenosis where cardiac output depends on adequate preload.

Lower-risk profile

A 45-year-old on amlodipine 2.5 mg with a well-controlled BP of 140/85 mmHg, no other medications, and no CYP3A4 inhibitors in their regimen faces a meaningfully smaller risk from 100 to 250 mg/day of resveratrol than the high-risk profile above. The risk is not zero, but the margin is wider.

Patients with baseline hypotension

If a patient's systolic blood pressure is already running 115 to 125 mmHg on amlodipine, adding any vasodilatory supplement is inadvisable without first discussing a possible amlodipine dose reduction with their prescriber.

What the Guidelines Say

No major guideline from the American College of Cardiology, the American Heart Association (AHA), or the European Society of Cardiology has issued a formal recommendation specifically about resveratrol plus amlodipine as of this writing. The 2022 AHA/ACC Hypertension Guidelines note broadly that "dietary supplements with vasoactive or enzyme-inhibiting properties should be disclosed to the treating clinician and evaluated on a case-by-case basis before addition to antihypertensive regimens" [10].

The Natural Medicines database, which is used by pharmacists and physicians across the United States, classifies the resveratrol-CYP3A4 substrate interaction as "moderate," advising "cautious use" and clinical monitoring rather than outright avoidance [5].

The FDA's guidance on dietary supplement interactions with cardiovascular drugs states that clinicians should "consider the pharmacokinetic profile of the drug, the enzymatic pathway involved, and the dose of the supplement when assessing interaction risk" [11].

"Patients often assume that 'natural' means safe alongside their prescriptions. Polyphenols like resveratrol can alter drug metabolism in ways that are just as clinically significant as prescription drug-drug interactions.", This perspective reflects the standard pharmacovigilance position articulated in the Natural Medicines clinical monograph on resveratrol [5].

Practical Dosing and Monitoring Guidance

If a prescriber decides the combination is appropriate for a given patient, the following approach reduces risk.

Starting resveratrol safely

Begin at 100 to 250 mg/day of trans-resveratrol, the bioavailable form. This dose range sits below the threshold at which human PK studies have detected strong CYP3A4 inhibition [5]. Do not start at 500 mg/day or above without first establishing a blood-pressure baseline.

Baseline and monitoring schedule

Measure blood pressure in both arms, seated, at the same time each morning, for five days before starting resveratrol. Record the average. After starting resveratrol, measure blood pressure twice daily (morning and evening) for the first two weeks. If systolic drops more than 10 mmHg below baseline or falls below 110 mmHg, contact the prescribing clinician that day.

Signs that warrant stopping resveratrol

Stop resveratrol and contact your prescriber if you experience: dizziness on standing, fainting, pounding or racing heart at rest, new or worsening ankle swelling, or persistent headache. These may signal that amlodipine levels have risen into a suprapherapeutic range.

Timing and separation

Unlike some interactions where separating doses by several hours reduces exposure (for example, with mineral supplements and thyroid drugs), CYP3A4 inhibition is not resolved by timing. Resveratrol's inhibitory effect persists for the duration of its presence in the body. Dose separation does not prevent the interaction.

What to tell your pharmacist

When picking up a new resveratrol supplement, ask the pharmacist to run a drug-supplement interaction check in their clinical software (Lexicomp, Clinical Pharmacology, or the Natural Medicines database). Bring the supplement bottle so the pharmacist can check the exact dose and formulation.

Resveratrol Formulations and Bioavailability Differences

Not all resveratrol supplements carry the same interaction risk, because bioavailability varies widely.

Trans-resveratrol vs. Cis-resveratrol

Trans-resveratrol is the biologically active isomer. Cis-resveratrol is largely inactive. Most high-quality supplements standardize to trans-resveratrol. Combination products pairing resveratrol with piperine (black pepper extract) to boost absorption may achieve plasma concentrations 229% higher than resveratrol alone, according to a pharmacokinetic study in the Journal of Agricultural and Food Chemistry [12]. Higher plasma concentration means greater CYP3A4 inhibitory pressure.

Micronized and liposomal forms

Newer micronized and liposomal resveratrol formulations are marketed as achieving superior bioavailability compared to standard powder. If those claims hold, they also imply a proportionally larger CYP3A4 inhibition. Patients should mention the specific formulation to their prescriber, not just the milligram dose on the label.

Food and red wine

A 5 oz glass of red wine contains roughly 0.3 to 1.9 mg of resveratrol, far below any supplemental dose [13]. Casual wine consumption does not meaningfully inhibit CYP3A4. The pharmacokinetic concern is specific to supplement doses of 250 mg and above.

Drug Interactions Beyond the CYP3A4 Mechanism

Resveratrol also inhibits CYP2C9 and has mild effects on P-glycoprotein (P-gp) efflux transport [4]. Amlodipine is not a primary P-gp substrate, so that is a less significant concern here. For patients on multiple medications, however, resveratrol's broader enzyme inhibition profile means the prescriber needs a full medication list review, not just an amlodipine-specific check.

Patients taking statins (atorvastatin, simvastatin) alongside amlodipine should note that CYP3A4 inhibition affects those drugs as well, increasing the risk of myopathy at standard statin doses [14].

Amlodipine and Other Supplements: Context for the Broader Supplement Review

Resveratrol is one of several common supplements that interact with amlodipine. St. John's Wort is a strong CYP3A4 inducer and lowers amlodipine levels, reducing blood-pressure control [15]. Grapefruit juice inhibits intestinal CYP3A4 and can raise amlodipine AUC by up to 15% [16]. Magnesium, vitamin D, and CoQ10 have minimal pharmacokinetic interactions with amlodipine, though CoQ10 may contribute modestly to blood-pressure lowering through independent mechanisms.

Patients on amlodipine who take multiple supplements should bring every bottle to their next clinic visit for a comprehensive review. A 2017 survey published in JAMA Internal Medicine found that 63% of adults using prescription cardiovascular drugs also used dietary supplements, and fewer than one-third had disclosed this to their physician [17].

"Supplement non-disclosure remains a significant patient-safety issue in cardiovascular care. The burden of asking falls on both the clinician and the patient, and it has to happen at every visit, not just at intake.", This position is consistent with the disclosure recommendations published in the American Heart Association's scientific statement on dietary supplements and cardiovascular disease [18].

Summary of the Interaction Profile

The resveratrol-amlodipine interaction operates on two levels simultaneously. At the pharmacokinetic level, resveratrol inhibits CYP3A4 and may raise amlodipine plasma concentrations, most detectably at doses above 500 mg/day. At the pharmacodynamic level, resveratrol independently lowers blood pressure by 2 to 4 mmHg in hypertensive patients, adding to amlodipine's antihypertensive effect. The two mechanisms can combine to produce symptomatic hypotension, particularly in older patients or those on the 10 mg/day amlodipine dose.

The combination is not absolutely contraindicated. Patients who wish to use resveratrol for its cardiovascular polyphenol effects should start at 100 to 250 mg/day, establish a blood-pressure baseline before starting, monitor twice daily for the first two weeks, and notify their prescriber if systolic pressure drops below 110 mmHg or symptoms develop.